Objective-Proprotein convertase subtilisin/kexin 9 (PCSK9) promotes the degradation of the low-density lipoprotein receptor (LDLR), and its gene is the third locus implicated in familial hypercholesterolemia. Herein, we investigated the role of PCSK9 in adipose tissue metabolism. Methods and Results-At 6 months of age, Pcsk9 Ϫ/Ϫ mice accumulated Ϸ80% more visceral adipose tissue than wild-type mice. This was associated with adipocyte hypertrophy and increased in vivo fatty acid uptake and ex vivo triglyceride synthesis. Moreover, adipocyte hypertrophy was also observed in Pcsk9 Ϫ/Ϫ Ldlr Ϫ/Ϫ mice, indicating that the LDLR is not implicated. Rather, we show here by immunohistochemistry that Pcsk9 Ϫ/Ϫ males and females exhibit 4-and Ϸ40-fold higher cell surface levels of very-low-density lipoprotein receptor (VLDLR) in perigonadal depots, respectively. Expression of PCSK9 in the liver of Pcsk9 Ϫ/Ϫ females reestablished both circulating PCSK9 and normal VLDLR levels. In contrast, specific inactivation of PCSK9 in the liver of wild-type females led to Ϸ50-fold higher levels of perigonadal VLDLR. Conclusion-In vivo, endogenous PCSK9 regulates VLDLR protein levels in adipose tissue. This regulation is achieved by circulating PCSK9 that originates entirely in the liver. PCSK9 is thus pivotal in fat metabolism: it maintains high circulating cholesterol levels via hepatic LDLR degradation, but it also limits visceral adipogenesis likely via adipose VLDLR regulation. (Arterioscler Thromb Vasc Biol. 2011;31:785-791.)
P roprotein convertase subtilisin/kexin 9 (PCSK9) is the ninth member of the family of proprotein convertases (encoded by the genes PCSK1 to PCSK9) that share identity with subtilisin and kexin. 1 The first 8 members of the family cleave protein precursors of hormones, growth factors, receptors, and transmembrane transcription factors that transit through or reside in the secretory pathway. 2 In contrast, PCSK9 has no known substrates but itself. It undergoes an autocatalytic cleavage of its N-terminal prosegment, 1, 3 which remains trapped in the catalytic pocket. 4 PCSK9 shortens the half-life of the low-density lipoprotein receptor (LDLR), 5 a process independent of its catalytic activity. 6 Gain-of-function mutations in the PCSK9 gene lead to autosomal dominant hypercholesterolemia, 7 as do mutations in the LDLR and APOB genes. Other PCSK9 mutations or polymorphisms responsible for loss of function result in hypocholesterolemia. 8 PCSK9 is highly expressed in the liver, 1 where it binds the LDLR and promotes its internalization and degradation in endosomal/lysosomal compartments. 5 Thus, mice lacking PCSK9 (Pcsk9 Ϫ/Ϫ ) exhibit a 2-to 3-fold increase of the LDLR protein in liver homogenates, and a substantial accumulation of the receptor at the hepatocyte cell surface. 9, 10 This leads to hypocholesterolemia (Ϫ40%), with a Ϸ5-fold drop in low-density lipoprotein (LDL) cholesterol levels. In humans, where 70% of cholesterol is associated with LDLs, versus only 30% in mice, the hypocholesterolemia due to PCSK9 deficiency is even more dramatic. Two women lacking functional PCSK9 exhibited LDL cholesterol levels of Ϸ0.4 mmol/L (15 mg/dL). 11, 12 PCSK9 is now considered a promising target to treat hypercholesterolemia and prevent coronary heart disease.
Human PCSK9 is abundant in plasma, 13 and analysis of mice that lack PCSK9 specifically in liver revealed that circulating PCSK9 originates primarily in this tissue. 10 Whether physiological levels of circulating PCSK9 affect the LDLR protein levels in peripheral tissues, independent of its local expression, is yet to be demonstrated.
Another issue is the ability of PCSK9 to target other receptors. The major binding site of PCSK9 to the LDLR involves its catalytic domain, which interacts with EGF-A, 1 of 3 EGF-like repeats present in the extracellular domain of the LDLR. 14 In the LDLR family, very-low-density lipoprotein receptor (VLDLR) and apolipoprotein E receptor 2 that are the 2 closest receptors to LDLR also contain an EGF-A repeat that shares Ϸ60% identity with the LDLR one. Ex vivo, the levels of both receptors were shown to be efficiently reduced on PCSK9 overexpression, 15, 16 suggesting that they are in vivo targets of PCSK9. Although apolipoprotein E receptor 2 is mainly present in brain, VLDLR is highly expressed in heart, skeletal muscle, and adipose tissue, where it lies at the surface of endothelial cells (see reviews 17, 18 ). Unlike the LDLR, the VLDLR is not regulated by cellular sterols and does not efficiently bind LDLs. Rather, it contributes to the delivery of fatty acids that derive from triglyceride-rich lipoproteins to peripheral tissues. It binds apolipoprotein E-enriched chylomicrons and VLDLs, intermediate density lipoproteins, and lipoprotein lipase, which hydrolyzes triglycerides into free fatty acids. These interactions are facilitated by heparan sulfate proteoglycans, which bind lipoproteins and lipoprotein lipase. The latter, like the VLDLR, is abundant in adipose tissue, heart, and muscle. Finally, free fatty acid internalization is facilitated by several proteins, including the translocase FAT/CD36. 19 Although PCSK9 is a key regulator of circulating LDL cholesterol levels, the question of its implication in the regulation of adipogenesis was raised by our seminal observation that mice lacking PCSK9 (Pcsk9 Ϫ/Ϫ ) accumulated abdominal fat. Furthermore, it has recently been reported that postprandial triglyceride levels were 2-fold lower in Pcsk9 Ϫ/Ϫ mice, suggesting enhanced clearance. 20 We therefore compared the adipose tissue of wild-type (WT) versus Pcsk9 Ϫ/Ϫ mice. Pcsk9 Ϫ/Ϫ mice indeed accumulated more visceral fat in an LDLR-independent manner. In vivo and ex vivo functional analyses demonstrated an increased fatty acid uptake and a higher triglyceride synthesis in the adipose tissue of Pcsk9 Ϫ/Ϫ males and females. VLDLR protein levels were significantly increased in the visceral adipose tissue of Pcsk9 Ϫ/Ϫ mice, consistent with the hypothesis that circulating PCSK9 promotes the degradation of the VLDLR in this tissue.
Methods

Animals and Treatments
All procedures were approved by the Clinical Research Institute of Montreal animal care committee. Pcsk9 Ϫ/Ϫ mice lacking the Pcsk9 proximal promoter and exon 1 have been described, 10 and they were since backcrossed 10 times to C57BL/6J mice. Ldlr Ϫ/Ϫ (C57BL/6J background; stock 002529) and Vldlr Ϫ/Ϫ (stock 002207) mice were from the Jackson Laboratory. Mice were housed in a specific pathogen-free facility under 12-hour light/12-hour dark cycles and fed a normal chow diet (Agribrands, St-Hubert, Quebec, Canada).
A Supplemental Methods section is available online at http://atvb.ahajournals.org.
Results
The Absence of PCSK9 Leads to Fat Accumulation in Perigonadal Depots
In 10-week-old mice fed a chow diet, perigonadal and perirenal masses were increased with significant or close to significant probability values (PՅ0.075) in Pcsk9 Ϫ/Ϫ males and Pcsk9 Ϫ/Ϫ females ( Figure 1 ). In 26-week-old (6-monthold) mice, the increase of perigonadal mass reached 77% and 60% in Pcsk9 Ϫ/Ϫ males and females, respectively, whereas the increase of perirenal mass reached 108% and 76%. No significant variations were observed in the mass of inguinal, pectoral, or brown fat pads (Supplemental Figure I) , indicating that fat accumulation mainly occurred in visceral adipose tissue. However, Pcsk9 Ϫ/Ϫ mice were not prone to obesity. Their body weights increased only slightly, by 4% to 8%, even when mice were fed a Western diet for 25 weeks after weaning (Supplemental Figure II) .
To determine whether fat accumulation was due to adipocyte hypertrophy or hyperplasia, paraffin sections of WT and Pcsk9 Ϫ/Ϫ perigonadal adipose tissue were analyzed ( Figure 2 ). The average number of adipocytes per mm 2 did not differ between WT males and females, but it was strongly reduced in both Pcsk9 Ϫ/Ϫ males (Ϫ46%) and females (Ϫ53%). With an estimated average adipocyte sectional area of Ϸ4080 versus 2060 m 2 , the Pcsk9 Ϫ/Ϫ adipocytes are expected to be Ϸ2.8-fold larger than WT adipocytes.
To elucidate whether hypertrophy is due to the loss of PCSK9 in perigonadal fat, we evaluated its expression level by quantitative reverse transcription-polymerase chain reaction. PCSK9 mRNA was Ϸ160-fold less abundant than in the liver (Supplemental Figure III) , the major expression site of PCSK9, thus raising the question of the potential role of circulating PCSK9. 
Circulating Triglyceride Levels Are Slightly Higher in Mice Lacking PCSK9
Circulating cholesterol was 32% and 40% lower in Pcsk9 Ϫ/Ϫ males and females, respectively, as previously reported for male mice. 9, 10 Conversely, plasma triglycerides were slightly increased in Pcsk9 Ϫ/Ϫ males (ϩ35%; not significant) and females (ϩ46%; Pϭ0.03). In agreement, fast protein liquid chromatography analyses showed triglyceride enrichment in very-low-density lipoprotein fractions in both males and females (Supplemental Figure IV ).
Dietary Lipid Uptake Is Increased in Pcsk9 ؊/؊ Adipose Tissue
To better define the molecular mechanisms leading to fat accumulation, WT and Pcsk9 Ϫ/Ϫ mice received a 3 H-oleate fat load by gavage after overnight fasting. Plasma triglycerides were measured over 3 hours (Supplemental Figure  V) . Their clearance was not significantly affected in Pcsk9 Ϫ/Ϫ mice, although a trend for faster clearance was observed in Pcsk9 Ϫ/Ϫ females. After 3 hours, mice were euthanized to evaluate the combined 3 H-triacylglycerol and 3 H-diacylglycerol content of perigonadal and inguinal pads, muscle, and liver ( Figure 3A ). 3 H-Oleate uptake into tissue represents the overall process of lipoprotein hydrolysis (primarily chylomicrons) coupled to fatty acid uptake and esterification into triglycerides. In males, 3 H-oleate incorporation increased in all Pcsk9 Ϫ/Ϫ tissues tested, especially in perigonadal and inguinal pads. In Pcsk9 Ϫ/Ϫ females, 3 H-oleate incorporation increased in perigonadal and inguinal pads, although to a lesser extent than in Pcsk9 Ϫ/Ϫ males, whereas the incorporation in muscle was the same in WT and Pcsk9 Ϫ/Ϫ females. Thus, the loss of PCSK9 favors a higher uptake of fatty acids by the adipose tissue in both genders. In contrast to Pcsk9 Ϫ/Ϫ males that exhibited 78% increased incorporation in the liver, Pcsk9 Ϫ/Ϫ females showed a 41% lower incorporation. However, because of high variations between mice, probability values (0.15 and 0.08) did not reach statistical significance ( Figure 3A , right panel).
Pcsk9 ؊/؊ Adipose Tissue Exhibits Increased Ex Vivo Triglyceride Synthesis
To evaluate the intrinsic ability of each tissue to synthesize triglycerides directly from glucose and fatty acids, pieces of perigonadal and inguinal fat, muscle, and liver were incubated with 14 C-glucose ( Figure 3B ). Glucose is the precursor of the intracellular triglyceride backbone glycerol-3phosphate. In these experiments, the contribution of lipoprotein binding and lipoprotein lipase-mediated lipolysis of dietary triglycerides is bypassed. Triglyceride synthesis was maintained or increased in all Pcsk9 Ϫ/Ϫ tissues tested, including male livers, in which triglyceride synthesis strongly increased (ϩ118%). In contrast, female Pcsk9 Ϫ/Ϫ liver exhibited a significant 53% drop, consistent with the 41% lower 3 H-oleate incorporation observed following the fat load. Together, these data suggest that PCSK9 deficiency leads to an increased fatty acid uptake that stimulates triglyceride synthesis in perigonadal (ϩ80% in males) and inguinal (ϩ93% in Pcsk9 Ϫ/Ϫ females; Pϭ0.1) pads.
Adipocyte Hypertrophy in Pcsk9 ؊/؊ Mice Is LDLR Independent
To examine whether adipocyte hypertrophy was dependent on PCSK9-mediated LDLR regulation, paraffin sections of perigonadal fat of mice lacking the LDLR and having either (Figure 4 ). In an Ldlr Ϫ/Ϫ background, the lack of PCSK9 (Ldlr Ϫ/Ϫ Pcsk9 Ϫ/Ϫ ) resulted in adipocyte hypertrophy, with 39% and 57% fewer adipocytes per mm 2 in males and females, respectively, similar to the 46% and 53% drops seen in Pcsk9 Ϫ/Ϫ mice (Figure 2 ). Note that in Ldlr Ϫ/Ϫ perigonadal depots, neither the size of the adipocytes ( Figure  4 ) nor PCSK9 expression (Supplemental Figure III) was significantly affected.
VLDLR Protein Levels Increase in Perigonadal Fat in the Absence of PCSK9
Because LDLR regulation by PCSK9 did not seem implicated in the adipose tissue phenotype, and because the VLDLR was shown to be targeted by PCSK9 ex vivo, 15, 16 we examined the possibility of its in vivo regulation by PCSK9.
Western blot analyses were unsuccessful with commercially available antibodies, and to our knowledge, adipose VLDLR has never been visualized by Western blot. 21, 22 Paraffin sections of perigonadal depots from 26-week-old mice were therefore analyzed by immunohistochemistry ( Figure 5 ). Image analysis (see Methods) revealed that lack of PCSK9 led to 4-and 43-fold increases in VLDLR labeling in males and females, respectively, revealing a strong VLDLR downregulation exerted by PCSK9 in this tissue, especially in females. In the absence of the LDLR, the loss of PCSK9 led to a similar 36-fold (PϽ0.0001) increase in VLDLR labeling in females but not in males. Note that VLDLR was not detected in Vldlr Ϫ/Ϫ control sections (Supplemental Figure VI) .
VLDLR mRNA levels were assessed in the same tissues by quantitative reverse transcription-polymerase chain reaction (Supplemental Figure VII) . Although similar in the adipose tissue of all male mice, VLDLR mRNA levels in Pcsk9 Ϫ/Ϫ females doubled, a difference that cannot account for the 43-fold increase in cell surface VLDLR protein levels. In the absence of LDLR, the loss of PCSK9 in females (Ldlr Ϫ/Ϫ Pcsk9 Ϫ/Ϫ ) was accompanied by a significant 35% drop in VLDLR mRNA relative to Ldlr Ϫ/Ϫ females, whereas the surface protein level was increased 36-fold. VLDLR mRNA upregulation is thus not responsible for VLDLR protein accumulation at the adipocyte cell surface. In the liver, where the VLDLR was not detectable by immunohistochemistry, VLDLR mRNA expression was 6-to 27-fold higher in females than in males (PՅ0.000005; Supplemental Figure  VII) , depending on the genotype, thus raising the possibility that PCSK9 may also affect VLDLR protein levels in female hepatocytes.
Neither lipoprotein lipase, which hydrolyzes triglycerides from triglyceride-rich lipoproteins, nor CD36, which translocates free fatty acids, was affected in perigonadal fat pads at the transcriptional level by the loss of PCSK9 or LDLR, except in Pcsk9 Ϫ/Ϫ females, where CD36 mRNA almost doubled (ϩ80%; online Figure VIII ). However, this 80% increase may be not essential because CD36 mRNA levels were not affected in Pcsk9 Ϫ/Ϫ males, in which fat accumulation and increased 3 H-oleate uptake were even more severe than in Pcsk9 Ϫ/Ϫ females, and not affected in the Ldlr Ϫ/Ϫ background.
Circulating PCSK9 Regulates Adipose VLDLR Protein
The poor expression of PCSK9 in perigonadal depots led us to examine the possible role of circulating PCSK9 in VLDLR protein regulation. We took advantage of the liver origin of circulating PCSK9. First, we expressed PCSK9 in the liver of Pcsk9 Ϫ/Ϫ mice using a transgene that expresses mouse PCSK9 under the control of the apolipoprotein E promoter 10 (Pcsk9 Ϫ/Ϫ Tg ϩ/0 ). This led to a 53-fold reduction of the VLDLR labeling observed in Pcsk9 Ϫ/Ϫ females ( Figure 6 , top panels) and to plasma PCSK9 levels that were Ϸ5-fold higher than WT ones ( Figure 6, right panel) . Second, we compared Pcsk9 flox/flox (equivalent to WT) mice with littermates carrying a transgene that expresses the Cre recombinase under the albumin promoter (Pcsk9 flox/flox Alb-cre ϩ/0 ) and thus lacking PCSK9 specifically in hepatocytes. 10 The relatively low levels of VLDLR protein observed in Pcsk9 flox/flox females, which do not differ from WT females in their levels of circulating PCSK9 (233 versus 238 ng/mL), was dramatically increased (53-fold) when PCSK9 was no longer expressed in the liver (Figure 6 , lower panels). In the latter mice, no circulating PCSK9 was detected by ELISA, confirming the unique liver origin of PCSK9 and high efficiency of Pcsk9 excision by Cre in hepatocytes. 10 Interestingly, plasma PCSK9 levels were significantly lower (Ϫ45%) in Vldlr Ϫ/Ϫ mice (Figure 6, right panel) , suggesting that liver PCSK9 is downregulated in the absence of the VLDLR. Altogether, these data show that circulating PCSK9 is responsible for the reduction of VLDLR protein levels in perigonadal depots.
Discussion
The purpose of our study was to gain insight into the role of PCSK9 in adipose tissue metabolism. We show herein that circulating PCSK9 regulates fat accumulation in adipocytes.
Pcsk9 Ϫ/Ϫ mice exhibited larger perigonadal (ϩ70%) and perirenal (ϩ90%) depots than WT mice, and the average volume of a perigonadal adipocyte was estimated to increase by 2.8-fold. Dietary fat hydrolysis and incorporation was increased in perigonadal and inguinal fat (from 1.5-to 2.6-fold) in both Pcsk9 Ϫ/Ϫ males and females, even though the inguinal fat mass was moderately increased in 10-week-old mice. In the same tissues, the intracellular triglyceride synthesis was maintained or increased, and no major changes were observed in WT and Pcsk9 Ϫ/Ϫ fatty acid catabolism evaluated by the number of disintegrations per minute associated with oxidation products, except an 81% increased oxidation in inguinal pads of Pcsk9 Ϫ/Ϫ females (not shown), likely leading to an underestimation of the 3 H incorporation in this tissue.
Although males and females shared the above phenotypes, a striking difference was observed in their liver metabolism: 3 H-oleate incorporation and triglyceride synthesis approximately doubled in the liver of Pcsk9 Ϫ/Ϫ males but were Ϸ2-fold reduced in the liver of Pcsk9 Ϫ/Ϫ females (Figure 3 , right panels). In addition, livers from 26-week-old Pcsk9 Ϫ/Ϫ mice did not exhibit any steatosis (not shown). This suggests that following a gavage, Pcsk9 Ϫ/Ϫ males have a higher potential to internalize abundant chylomicron remnants than Pcsk9 Ϫ/Ϫ females. Figure 6 . Adipose VLDLR protein is regulated by circulating PCSK9. VLDLR immunohistochemistry was performed on female perigonadal sections from either Pcsk9 Ϫ/Ϫ littermates that did not or did receive a transgene expressing PCSK9 in the liver (a and b; ϩcirculating PCSK9) or from Pcsk9 flox/flox (equivalent to WT) littermates that did not or did receive a transgene expressing Cre inactivating specifically the Pcsk9 gene in hepatocytes (c and d; Ϫcirculating PCSK9). Average (ϮSEM) VLDLR labeling and plasma PCSK9 levels for these mice are shown, as well as for Vldlr Ϫ/Ϫ mice as negative controls. nϭ4 to 5 mice per genotype. *PՅ0.05, **PՅ0.005, ***PՅ0.0005.
We examined the adipose tissue of Ldlr Ϫ/Ϫ Pcsk9 Ϫ/Ϫ mice and found that the lack of PCSK9 led to adipocyte hypertrophy independently from the LDLR. This is in agreement with low LDLR levels in perigonadal fat, in which LDLR mRNA is ϳ8-fold lower than in the liver (Supplemental Figure VIII) .
As a candidate target of PCSK9 in fat, the VLDLR presented several key properties. It is Ϸ60% identical to LDLR, it was downregulated ex vivo by PCSK9, 15, 16 and it is a major lipoprotein receptor in adipose tissue implicated in triglyceride metabolism. 18 Compared with WT mice, Pcsk9 Ϫ/Ϫ males and females had 4-and 43-fold more cell surface VLDLR in perigonadal fat, respectively. In Ldlr Ϫ/Ϫ Pcsk9 Ϫ/Ϫ females, a similar 36-fold increase was observed. Together, these data reveal that PCSK9 exerts, in an LDLRindependent manner, a strong control on adipocyte VLDLR, especially in females. It is tempting to attribute the increased visceral adipogenesis to VLDLR upregulation. In agreement with this hypothesis, Vldlr Ϫ/Ϫ mice were reported to exhibit 15% to 20% lower body weights, reduced (Ϫ40%) perigonadal fat and adipocyte size, and impaired fatty acid uptake, 22 whereas Pcsk9 Ϫ/Ϫ mice exhibited slightly higher body weights, fat accumulation, larger adipocytes, and higher fatty acid uptake (this study). Additional studies in mice lacking both PCSK9 and VLDLR will be required to verify that the latter phenotypes are lost in the absence of the VLDLR.
Finally, the analysis of different mouse models revealed that circulating, and not local, PCSK9 is responsible for adipose VLDLR protein regulation. Expression of PCSK9 in the liver of Pcsk9 Ϫ/Ϫ mice normalized the VLDLR labeling, whereas removal of PCSK9 from the liver of normal mice led to a dramatic increase in adipose VLDLR protein. Thus, this study provides the first evidence for an in vivo role of endogenous levels of circulating PCSK9. In WT mice, the above data suggest that the latter is responsible for the degradation of Ϸ75% and Ն95% of the perigonadal surface VLDLR in males and females, respectively.
Curiously, although the absence of PCSK9 led to Ϸ10-fold higher levels of VLDLR in female perigonadal pads than in male ones, similar phenotypes in terms of adipocyte size and perigonadal mass were observed. Whether endogenous levels of circulating PCSK9 also target extrahepatic LDLR remains to be determined. Only huge quantities of PCSK9 obtained by injection of purified PCSK9 or adenoviral overexpression were reported to reduce LDLR levels in lung, adipose, kidney, or ileum. 23 Because plasma PCSK9 originates exclusively in the liver, its expression in this organ could be pivotal for the coordination between peripheral fatty acid uptake and liver lipoprotein uptake, via the regulation of surface levels of VLDLR and LDLR. The function of liver PCSK9 may reside in its ability to slow down the catabolism of lipoproteins in a coordinated manner and to maintain proper circulating levels of cholesterol and triglycerides. For example, we have previously shown that lesions observed in the regenerating liver of Pcsk9 Ϫ/Ϫ mice were efficiently prevented by feeding the mice a high-cholesterol diet, indicating that, in mouse, loss of PCSK9 leads to a critical hypocholesterolemia. In agreement with its key regulatory role, PCSK9 is regulated at the transcriptional level by sterols, 24 insulin, glucagon, ethi-nylestradiol, and fasting [25] [26] [27] but also at the protein level by hepatic furin. 28 Because human PCSK9 targets ex vivo human VLDLR 15 and binds in vitro mouse VLDLR, 16 PCSK9 may also target VLDLR in humans. Whether an increased visceral fat deposition also occurs in humans lacking functional PCSK9 remains to be elucidated. Perigonadal fat is part of what is called the visceral adipose tissue, which correlates directly with obesity-related metabolic disease and coronary heart disease. However, it was recently reported that in obese patients with similar levels of visceral adipose tissue, metabolic complications were more prevalent in those exhibiting higher intrahepatic triglycerides. 29 In a clinical perspective, because Pcsk9 Ϫ/Ϫ mice do not develop liver steatosis and are not prone to obesity, the administration of a PCSK9 inhibitor developed for hypercholesterolemia treatment should not result in adverse effects.
